|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INTS4 |
Gene summary for INTS4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INTS4 | Gene ID | 92105 |
| Gene name | integrator complex subunit 4 | |
| Gene Alias | INT4 | |
| Cytomap | 11q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96HW7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92105 | INTS4 | LZE8T | Human | Esophagus | ESCC | 7.15e-04 | 1.66e-01 | 0.067 |
| 92105 | INTS4 | LZE24T | Human | Esophagus | ESCC | 2.92e-04 | 1.50e-01 | 0.0596 |
| 92105 | INTS4 | P1T-E | Human | Esophagus | ESCC | 1.69e-02 | 1.50e-01 | 0.0875 |
| 92105 | INTS4 | P2T-E | Human | Esophagus | ESCC | 1.04e-12 | 1.15e-01 | 0.1177 |
| 92105 | INTS4 | P4T-E | Human | Esophagus | ESCC | 1.97e-04 | 1.49e-01 | 0.1323 |
| 92105 | INTS4 | P5T-E | Human | Esophagus | ESCC | 1.08e-09 | 1.08e-01 | 0.1327 |
| 92105 | INTS4 | P8T-E | Human | Esophagus | ESCC | 2.70e-09 | 8.96e-02 | 0.0889 |
| 92105 | INTS4 | P10T-E | Human | Esophagus | ESCC | 3.56e-13 | 1.10e-01 | 0.116 |
| 92105 | INTS4 | P11T-E | Human | Esophagus | ESCC | 1.81e-07 | 3.01e-01 | 0.1426 |
| 92105 | INTS4 | P12T-E | Human | Esophagus | ESCC | 2.03e-15 | 2.66e-01 | 0.1122 |
| 92105 | INTS4 | P15T-E | Human | Esophagus | ESCC | 1.66e-12 | 2.76e-01 | 0.1149 |
| 92105 | INTS4 | P16T-E | Human | Esophagus | ESCC | 1.05e-10 | 2.46e-01 | 0.1153 |
| 92105 | INTS4 | P17T-E | Human | Esophagus | ESCC | 1.48e-06 | 2.19e-01 | 0.1278 |
| 92105 | INTS4 | P19T-E | Human | Esophagus | ESCC | 3.75e-02 | 2.80e-01 | 0.1662 |
| 92105 | INTS4 | P21T-E | Human | Esophagus | ESCC | 2.01e-10 | 1.70e-01 | 0.1617 |
| 92105 | INTS4 | P22T-E | Human | Esophagus | ESCC | 1.71e-09 | 4.18e-02 | 0.1236 |
| 92105 | INTS4 | P23T-E | Human | Esophagus | ESCC | 1.29e-05 | 1.65e-01 | 0.108 |
| 92105 | INTS4 | P24T-E | Human | Esophagus | ESCC | 8.95e-14 | 7.81e-02 | 0.1287 |
| 92105 | INTS4 | P26T-E | Human | Esophagus | ESCC | 1.42e-10 | 9.26e-02 | 0.1276 |
| 92105 | INTS4 | P27T-E | Human | Esophagus | ESCC | 1.56e-09 | 1.12e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INTS4 | SNV | Missense_Mutation | novel | c.2299N>A | p.Ala767Thr | p.A767T | Q96HW7 | protein_coding | tolerated(0.52) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INTS4 | SNV | Missense_Mutation | novel | c.559N>T | p.Asp187Tyr | p.D187Y | Q96HW7 | protein_coding | deleterious(0.03) | possibly_damaging(0.659) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INTS4 | SNV | Missense_Mutation | c.296N>C | p.Leu99Ser | p.L99S | Q96HW7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INTS4 | SNV | Missense_Mutation | c.1369G>C | p.Glu457Gln | p.E457Q | Q96HW7 | protein_coding | tolerated(0.11) | probably_damaging(0.992) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| INTS4 | SNV | Missense_Mutation | novel | c.667N>A | p.His223Asn | p.H223N | Q96HW7 | protein_coding | deleterious(0.01) | benign(0.303) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| INTS4 | SNV | Missense_Mutation | novel | c.52C>G | p.Gln18Glu | p.Q18E | Q96HW7 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INTS4 | insertion | Frame_Shift_Ins | novel | c.135dupA | p.Ala46SerfsTer40 | p.A46Sfs*40 | Q96HW7 | protein_coding | TCGA-BH-A0E9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | ||
| INTS4 | deletion | Frame_Shift_Del | novel | c.342delC | p.Ile115SerfsTer13 | p.I115Sfs*13 | Q96HW7 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| INTS4 | SNV | Missense_Mutation | c.2081N>T | p.Ser694Leu | p.S694L | Q96HW7 | protein_coding | tolerated(0.23) | benign(0) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| INTS4 | SNV | Missense_Mutation | novel | c.2849A>C | p.Lys950Thr | p.K950T | Q96HW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.815) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |